Back to Saudi Arabia Overview
Variations & Renewals
Changes, Renewal & Lifecycle Support (SFDA)
A Change Can Affect the Regulatory Basis of the MDMA. Design, software, manufacturing, supplier, sterilization, labeling and intended-purpose changes should be assessed before implementation because they may affect technical documentation, marketing authorization information, QMS controls or local regulatory records.
When This Support Is Needed
Design, raw material, or engineering specification changes planned for an MDMA-authorized device
Manufacturing site transfer, contract sterilizer change, or critical component supplier replacement
Releasing a software version update, cybersecurity patch, or new algorithmic capability
Updating product labeling, packaging artwork, or expanding clinical intended use claims
An MDMA marketing authorization or establishment license renewal date is approaching
What We Challenge Before Submission
Does the planned engineering change alter the established SFDA risk classification or intended use?
Does the change require formal SFDA pre-approval prior to commercial distribution in the Kingdom?
Do existing pre-clinical bench, biocompatibility, and sterilization test reports still represent the modified device?
Are changes to legal manufacturer corporate data or site addresses reflected across all certificates?
Is the MDMA renewal application initiated well in advance of the statutory expiration deadline?
Our Lifecycle Change Management Scope
Regulatory change impact assessment against SFDA regulations and guidance
Change categorization and determination of notification vs formal variation requirements
Technical file update strategy and verification/validation evidence gap closure
Risk management file review and ISO 14971 benefit-risk re-evaluation
Clinical evaluation and IVD performance evidence impact assessment
Manufacturing site, sterilizer, and ISO 13485 QMS certificate change management
Arabic/English label and IFU revision review and harmonization
Saudi-DI UDI database update and trigger analysis
MDMA marketing authorization renewal planning, drafting, and GHAD submission
Authorized Representative mandate updates and commercial distributor amendments
Post-market regulatory record and establishment license maintenance
Lifecycle Assessment Rule:
We ask whether the change alters the regulatory basis on which safety, performance, classification or authorization was demonstrated. That determines whether the action is a technical-file update, validation requirement, notification, authorization amendment or another regulatory step.
Manage SFDA MDMA Variations and Renewal Submissions
Our regulatory strategists assess change impact, submit variation applications via GHAD, and manage MDMA renewals.